| |
GLIA's H&Q presentation press release is a typical low key PR effort. There is no new information. So, the quality of the presentation will be the factor that determines whether we will see an influx of new money into GLIA or not.
Best regards
John de C
Gliatech to Present at Hambrecht & Quist Technology Conference
CLEVELAND, Jan. 10 /PRNewswire/ -- Gliatech Inc. (Nasdaq: GLIA - news) will appear at the 18th Annual Hambrecht & Quist Healthcare Conference January 10-13th in San Francisco. Following is a brief overview of the presentation that will be delivered at the conference on Monday, January 10th at 8:30 AM. Gliatech's Chairman and Chief Executive Officer, Thomas O. Oesterling, Ph.D. will be presenting an overview of the company and milestones for the coming year. Current development initiatives at Gliatech are targeting products to improve surgical outcomes and to treat neurological disorders.
Gliatech's biosurgery business includes the ADCON® products, which are aimed at preventing postsurgical adhesion formation, and products using monoclonal antibodies to treat acute inflammation. The members of Gliatech's ADCON® family of anti-adhesion barrier products are: (i) ADCON®-L, for lumbar spine surgeries, currently available in the U.S., Europe and other selected international countries; (ii) ADCON®-T/N, for tendon and peripheral nerve surgeries, currently available in Europe and selected international countries and under an IDE in the U.S., (iii) ADCON®-P, for pelvic and gynecological surgeries, and currently in a pivotal clinical trial in the U.S., (iv) ADCON®-A, for abdominal and colorectal surgeries, and currently in a pilot clinical trial in the U.S., (v) ADCON®-I, for implant surgeries, and (vi) ADCON®-C, for cardiac surgeries. ADCON®-I and ADCON®-C are currently undergoing preclinical studies.
The Company's biosurgery programs in acute inflammation are utilizing a proprietary monoclonal antibody that blocks the inappropriate activation of the complement pathway and will be useful in a variety of indications where inflammation causes unwanted effects, such as coronary bypass surgery, myocardial infarction and stroke.
Gliatech's neurological disorder programs are focused on developing drugs to modulate the cognitive state of the nervous system and schizophrenia. Perceptin(TM) is the Company's selective histamine H3 receptor antagonist which is being developed for potential use in central nervous system diseases involving attention/learning or sleep disorders. The potential uses for Perceptin(TM) include Attention Deficit Hyperactivity Disorder, dementia associated with Alzheimer's Disease and sleep disorders, including narcolepsy. Perceptin(TM) is entering Phase II clinical trials.
Gliatech has a drug development program aimed at developing novel inhibitors of central nervous system glycine transporters. The Company has identified prototype inhibitors of this transporter and is investigating these and related compounds for their potential utility in the treatment of schizophrenia and dementia.
Gliatech is a leader in the discovery and development of therapeutic products based on the properties of glial cells. The Company applies its core glial research to developing innovative products for major unmet human health care needs. Gliatech was founded in 1988 and has 90 employees, over half of whom are dedicated to research. |
|
